The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

BACKGROUND: KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting (G12C)KRAS specifically, but therapeutic options for other mutant forms of KRAS are limited, largely because the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., Holovanchuk, D., Pedersen, M., McLeary, R., Lorigan, P., Dhomen, N., Fisher, C., Banerji, U., Dean, E., Krebs, M.G., Gore, M., Larkin, J., Marais, R., Springer, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839839/
https://www.ncbi.nlm.nih.gov/pubmed/33130216
http://dx.doi.org/10.1016/j.annonc.2020.10.483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839839/
https://www.ncbi.nlm.nih.gov/pubmed/33130216
http://dx.doi.org/10.1016/j.annonc.2020.10.483

Ejemplares similares